CMS holds off on Medicaid price data
CMS will not publicly release current average manufacturer prices(AMP) slated to be used to calculate Medicaid reimbursement ongenerics, according to administrator Mark McClellan. With inputfrom pharmacy, the agency has concluded that the definition of AMPmust be revised to reflect the prices retail pharmacies actuallypay for generics.
CMS will not publicly release current average manufacturer prices (AMP) slated to be used to calculate Medicaid reimbursement on generics, according to administrator Mark McClellan. With input from pharmacy, the agency has concluded that the definition of AMP must be revised to reflect the prices retail pharmacies actually pay for generics. A proposed rule on the new definition will be open for public comment later this year, he told attendees at NCPA's annual legislative and government conference.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
To go to the Drug Topics homepage, click here http://www.drugtopics.com.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
